Galectin-8 and -9 as prognostic factors for cervical cancer.
Cervical cancer
Galectin-8
Galectin-9
Survival
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
28
11
2020
accepted:
09
02
2022
pubmed:
5
4
2022
medline:
16
9
2022
entrez:
4
4
2022
Statut:
ppublish
Résumé
Galectins are carbohydrate-binding proteins with multiple effects on cell biology. Research shows that they play an important role in tumor development and progression. Therefore, in this study, the presence of Galectin-8 and -9 (Gal), both already known as prognostic factors in other tumor entities, were investigated in cervical cancer. Our aim was to examine the association of Gal-8 and -9 expression with histopathological markers and survival of the patients. Gal-8 and -9 expression was investigated in 250 cervical cancer samples by immunohistochemistry. The staining was evaluated using the immunoreactive score (IRS). The results were correlated to clinical and pathological data. The correlation of Gal-8 and -9 expression with overall and relapse-free survival was analyzed. Expression of Gal-8 was associated with negative N-status and lower FIGO status. Detection of Gal-9 was connected to negative N-status and lower grading regarding all specimens. A correlation of Gal-9 with lower FIGO status was detected for squamous cell carcinoma (SCC) only. Expression of Gal-8 was associated with relapse-free survival of SCC patients in a positive manner. Gal-9 expression was associated with better overall survival. Our results suggest that expression of both galectins is inversely associated with tumor stage and progression. Gal-8 expression is associated with relapse-free survival of patients with SCC, while presence of Gal-9 in cervical cancer is associated with a better prognosis in regard of overall survival.
Identifiants
pubmed: 35377045
doi: 10.1007/s00404-022-06449-9
pii: 10.1007/s00404-022-06449-9
pmc: PMC9470666
doi:
Substances chimiques
Galectins
0
LGALS8 protein, human
0
LGALS9 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1211-1220Informations de copyright
© 2022. The Author(s).
Références
Tumour Biol. 2016 Sep;37(9):12635-12642
pubmed: 27444274
Biochemistry. 2011 Sep 20;50(37):7842-57
pubmed: 21848324
J Infect Dis. 2001 Sep 15;184(6):682-90
pubmed: 11517428
Asian Pac J Cancer Prev. 2012;13(11):5489-95
pubmed: 23317205
J Biol Chem. 1997 Mar 7;272(10):6416-22
pubmed: 9045665
Biochim Biophys Acta. 1999 Dec 6;1473(1):172-85
pubmed: 10580137
Cancers (Basel). 2020 Apr 12;12(4):
pubmed: 32290551
Med Oncol. 2016 Jan;33(1):8
pubmed: 26708131
Int J Mol Sci. 2019 May 29;20(11):
pubmed: 31146370
BMC Cancer. 2018 Jan 30;18(1):105
pubmed: 29378529
Biochim Biophys Acta. 2010 Feb;1800(2):181-9
pubmed: 19616076
Clin Microbiol Rev. 2003 Jan;16(1):1-17
pubmed: 12525422
Gut. 2002 Mar;50(3):392-401
pubmed: 11839721
Int J Mol Sci. 2018 Jan 22;19(1):
pubmed: 29361803
Cancer. 2003 Apr 15;97(8):1849-58
pubmed: 12673710
Breast J. 2006 Sep-Oct;12(5 Suppl 2):S196-200
pubmed: 16959001
Clin Cancer Res. 2005 Apr 15;11(8):2962-8
pubmed: 15837748
J Med Genet. 2005 Aug;42(8):e49
pubmed: 16061555
Int Arch Allergy Immunol. 2000 May;122 Suppl 1:6-9
pubmed: 10867499
Cell. 1994 Feb 25;76(4):597-8
pubmed: 8124704
PLoS One. 2013 Dec 10;8(12):e81799
pubmed: 24339967
Res Pharm Sci. 2018 Dec;13(6):557-565
pubmed: 30607153
FASEB J. 2011 Jan;25(1):242-54
pubmed: 20876211
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Biochem. 2007 Feb;141(2):157-72
pubmed: 17167046
Gene. 2001 Aug 22;274(1-2):253-62
pubmed: 11675018
J Cancer Res Clin Oncol. 2008 Aug;134(8):899-907
pubmed: 18264727
J Biol Chem. 1995 Feb 17;270(7):3447-53
pubmed: 7852431
Front Immunol. 2019 Jul 11;10:1594
pubmed: 31354733
J Exp Med. 2020 Feb 3;217(2):
pubmed: 31873723
Histol Histopathol. 2001 Jul;16(3):861-8
pubmed: 11510978
J Cell Sci. 2000 Jul;113 ( Pt 13):2385-97
pubmed: 10852818
Biochim Biophys Acta. 2013 Aug;1836(1):177-85
pubmed: 23648450
Glycobiology. 2016 Oct;26(10):1048-1058
pubmed: 27287437
Nat Commun. 2013;4:1613
pubmed: 23511477
Urol Int. 2011;87(2):143-50
pubmed: 21757871
Gynecol Oncol. 2003 Sep;90(3 Pt 2):S16-21
pubmed: 13129491
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
J Cell Sci. 2018 May 1;131(9):
pubmed: 29717004
Nat Rev Cancer. 2005 Jan;5(1):29-41
pubmed: 15630413
Glycobiology. 2019 Jan 1;29(1):22-35
pubmed: 30383222
PLoS One. 2015 Jun 12;10(6):e0129119
pubmed: 26066796
Mol Biol Evol. 2004 Jul;21(7):1177-87
pubmed: 14963092
Biochim Biophys Acta. 2014 Feb;1842(2):284-92
pubmed: 24333696
Glycobiology. 2014 Oct;24(10):907-14
pubmed: 24939370